Intensity Therapeutics (INTS) Stock Price, News & Analysis

Company Overview

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent. The formulation is designed to improve drug penetration within tumors while potentially activating the immune system to recognize and attack cancer cells at treated and untreated tumor sites.

INT230-6 has been evaluated in clinical studies involving patients with advanced solid tumors, including in combination with immune checkpoint inhibitors. The product remains investigational and has not been approved for commercial use. Intensity Therapeutics is based in Shelton, Connecticut, and its activities are primarily focused on advancing its oncology pipeline through clinical development and research collaborations.

Key Stats

• Today's Range: $3.30 to $3.58
• 50-Day Range: $3.18 to $4.89
• 52-Week Range: $3.00 to $15.75
• Volume: 2,201 shs
• Average Volume: 37,771 shs
• Market Capitalization: $11.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Intensity Therapeutics Stock Analysis - MarketRank™

Intensity Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 438th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Intensity Therapeutics has a consensus price target of $7.00, representing about 98.9% upside from its current price of $3.52.

Amount of Analyst Coverage

Intensity Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intensity Therapeutics are expected to grow in the coming year, from ($2.64) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intensity Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intensity Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intensity Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.91% of the float of Intensity Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intensity Therapeutics has a short interest ratio ("days to cover") of 3.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intensity Therapeutics has recently increased by 129.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intensity Therapeutics does not currently pay a dividend.

Dividend Growth

Intensity Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Intensity Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.60% of the stock of Intensity Therapeutics is held by insiders.

Percentage Held by Institutions

3.74% of the stock of Intensity Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INTS
• CIK: 1567264
• Web: www.intensitytherapeutics.com
• Phone: 203 221 7381
• Fax: N/A
• Employees: 2,021
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Intensity Therapeutics: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +96.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -116.61%
• Return on Assets: -94.01%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.00
• Quick Ratio: 5.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.94 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 3,260,000
• Free Float: 3,017,000
• Market Cap: $11.63 million
• Optionable: Not Optionable
• Beta: 2.78